This startup produces DNA blueprints for new proteins based on plain-text explanations by researchers of what specific traits or properties they’re aiming to replicate. Proteins, of course, form the basis for many drug treatments and gene therapies, along with agricultural innovations (like designs for more resilient or productive crops). The hope is that by making microbiology more “programmable,” Profluent will open the door to blockbuster drugs and related breakthroughs. Sort of a best case scenario for generative #Artificial Intelligence tools, even if we don’t reach AGI in the next few years. The company raised $106 million in seed funding from investors including Jeff Bezos’s Bezos Expeditions fund. #Science is awesome 🧬🦾🚀🤯 https://www.forbes.com/si..